Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics

[1]  P. Kantoff,et al.  Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors , 2021, Clinical Cancer Research.

[2]  D. Spratt,et al.  Racial disparities in prostate cancer among black men: epidemiology and outcomes , 2021, Prostate Cancer and Prostatic Diseases.

[3]  C. Drake,et al.  Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T , 2021, Journal of the National Cancer Institute.

[4]  D. Spratt,et al.  Drivers of racial disparities in prostate cancer trial enrollment , 2021, Prostate Cancer and Prostatic Diseases.

[5]  Randy V. Bradley,et al.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences , 2021, Communications biology.

[6]  K. Owzar,et al.  A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate‐resistant prostate cancer , 2021, Cancer.

[7]  P. Kantoff,et al.  Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry , 2021, JCO global oncology.

[8]  N. Mitsiades,et al.  Genomic landscape of advanced prostate cancer in racial minority populations: Real-world experience in a safety-net hospital oncology clinic. , 2021 .

[9]  Wei Zhang,et al.  Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer , 2021, Acta Pharmacologica Sinica.

[10]  Z. Szallasi,et al.  Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles , 2021, medRxiv.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  W. Willett,et al.  Does the High Prevalence of Vitamin D Deficiency in African Americans Contribute to Health Disparities? , 2021, Nutrients.

[13]  K. D. Sørensen,et al.  Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction , 2021, Nature genetics.

[14]  M. Harrison,et al.  Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer , 2020, JCO precision oncology.

[15]  James D. Murphy,et al.  Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration , 2020, Cancer.

[16]  M. Goodman,et al.  Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer , 2020, JAMA network open.

[17]  P. Kantoff,et al.  Racial Differences in Genomic Profiling of Prostate Cancer. , 2020, The New England journal of medicine.

[18]  F. Boccardo,et al.  BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications , 2020, Journal of oncology.

[19]  Navnath S. Gavande,et al.  Pro-inflammatory cytokines and chemokines initiate multiple prostate cancer biologic pathways of cellular proliferation, heterogeneity and metastasis in a racially diverse population and underlie the genetic/biologic mechanism of racial disparity: Update. , 2020, Urologic oncology.

[20]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Joshua D. Campbell,et al.  Genomic Profiling of Prostate Cancers from Men with African and European Ancestry , 2020, Clinical Cancer Research.

[22]  P. Kantoff,et al.  Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[23]  A. Caspi,et al.  Association of Neighborhood Disadvantage in Childhood With DNA Methylation in Young Adulthood , 2020, JAMA network open.

[24]  N. Makridakis,et al.  Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians , 2020, Oncogene.

[25]  Nakul M. Shah,et al.  A genomic and epigenomic atlas of prostate cancer in Asian populations , 2020, Nature.

[26]  P. Kantoff,et al.  Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry , 2020, Prostate Cancer and Prostatic Diseases.

[27]  David A. Bader,et al.  Tumour metabolism and its unique properties in prostate adenocarcinoma , 2020, Nature Reviews Urology.

[28]  T. Rebbeck,et al.  Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry , 2020, PLoS genetics.

[29]  James D. Murphy,et al.  Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system , 2020, Cancer.

[30]  J. Gu,et al.  Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients , 2020, EBioMedicine.

[31]  E. Platz,et al.  Racial Difference in Prostate Cancer Cell Telomere Lengths in Men with Higher Grade Prostate Cancer: A Clue to the Racial Disparity in Prostate Cancer Outcomes , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[32]  Shailesh Singh,et al.  Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer , 2019, Cancers.

[33]  H. Mei,et al.  Racial differences in distribution of fatty acids in prostate cancer and benign prostatic tissues , 2019, Lipids in Health and Disease.

[34]  R. Kittles,et al.  Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity , 2019, AntiCancer Research.

[35]  M. Terris,et al.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.

[36]  A. Chinnaiyan,et al.  Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer , 2019, Nature.

[37]  V. Hayes,et al.  TMPRSS2‐ERG fusions linked to prostate cancer racial health disparities: A focus on Africa , 2019, The Prostate.

[38]  M. Rubin,et al.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. , 2019, Cancer cell.

[39]  Danielle M. Crookes,et al.  The weathering hypothesis as an explanation for racial disparities in health: a systematic review. , 2019, Annals of epidemiology.

[40]  D. Olmos,et al.  BRCA2 and Other DDR Genes in Prostate Cancer , 2019, Cancers.

[41]  R. Kittles,et al.  Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[42]  M. Loda,et al.  Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer , 2018, Proceedings of the National Academy of Sciences.

[43]  S. Ambs,et al.  Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population , 2018, Prostate Cancer and Prostatic Diseases.

[44]  F. Saad,et al.  Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY , 2018, Clinical Cancer Research.

[45]  Jianfeng Xu,et al.  Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men. , 2018, Cancer research.

[46]  Yuzhuo Wang,et al.  Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) models , 2018, The Prostate.

[47]  K. Cooney,et al.  Rare germline mutations in African American men diagnosed with early‐onset prostate cancer , 2018, The Prostate.

[48]  B. Mahal,et al.  Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance , 2018, Cancer.

[49]  R. Marioni,et al.  Social adversity and epigenetic aging: a multi-cohort study on socioeconomic differences in peripheral blood DNA methylation , 2017, Scientific Reports.

[50]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[51]  Michael Ittmann,et al.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. , 2017, Cancer research.

[52]  H. Wu,et al.  CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  S. Knapp,et al.  Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer , 2017, Nature Communications.

[54]  R. Kittles,et al.  Prostatic compensation of the vitamin D axis in African American men. , 2017, JCI insight.

[55]  E. Jacobs,et al.  Race and BMI modify associations of calcium and vitamin D intake with prostate cancer , 2017, BMC Cancer.

[56]  Paolo Vineis,et al.  Biological marks of early-life socioeconomic experience is detected in the adult inflammatory transcriptome , 2016, Scientific Reports.

[57]  C. Creighton,et al.  MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. , 2016, Cancer research.

[58]  S. Myong,et al.  Oxidative guanine base damage regulates human telomerase activity , 2016, Nature Structural &Molecular Biology.

[59]  J. Jackson,et al.  Racial Discrimination, John Henryism, and Depression Among African Americans , 2016, The Journal of black psychology.

[60]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[61]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[62]  Paola Lecca,et al.  SPOP mutation leads to genomic instability in prostate cancer , 2015, eLife.

[63]  William A Satariano,et al.  The impact of neighborhood social and built environment factors across the cancer continuum: Current research, methodological considerations, and future directions , 2015, Cancer.

[64]  Ruth Etzioni,et al.  Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2015, JAMA oncology.

[65]  T. Daskivich,et al.  Racial parity in tumor burden, treatment choice and survival outcomes in men with prostate cancer in the VA healthcare system , 2014, Prostate Cancer and Prostatic Disease.

[66]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[67]  Peng Lee,et al.  Lipid metabolism in prostate cancer. , 2014, American journal of clinical and experimental urology.

[68]  K. Attwood,et al.  Androgen Receptor Mutations and Polymorphisms in African American Prostate Cancer , 2014, International journal of biological sciences.

[69]  S. Plymate,et al.  The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer , 2014, Hormones and Cancer.

[70]  E. Platz,et al.  Racial variation in sex steroid hormone concentration in black and white men: a meta‐analysis , 2014, Andrology.

[71]  R. Kittles,et al.  Vitamin D Deficiency Predicts Prostate Biopsy Outcomes , 2014, Clinical Cancer Research.

[72]  Ji-Xin Cheng,et al.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.

[73]  M. Loda,et al.  A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis , 2014, EMBO molecular medicine.

[74]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.

[75]  E. Garrett-Mayer,et al.  Vitamin D3 supplementation, low-risk prostate cancer, and health disparities , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[76]  M. Mori,et al.  Agent Orange as a risk factor for high‐grade prostate cancer , 2013, Cancer.

[77]  Andrew J Armstrong,et al.  Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. , 2013, Endocrine-related cancer.

[78]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[79]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[80]  S. Ambs,et al.  Biological determinants of health disparities in prostate cancer , 2013, Current opinion in oncology.

[81]  A. Rundle,et al.  Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. , 2013, Carcinogenesis.

[82]  Clara Correia-Melo,et al.  Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence , 2012, Nature Communications.

[83]  L. Chung,et al.  Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.

[84]  S. Bigler,et al.  A Retrospective Study on Pathologic Features and Racial Disparities in Prostate Cancer , 2011, Prostate cancer.

[85]  D. Tindall,et al.  Androgen receptor signaling in prostate cancer development and progression , 2011, Journal of carcinogenesis.

[86]  T. Brand,et al.  Racial/Ethnic Patterns in Prostate Cancer Outcomes in an Active Surveillance Cohort , 2011, Prostate cancer.

[87]  S. Freedland,et al.  Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men , 2011, Prostate Cancer and Prostatic Diseases.

[88]  M. Uhlén,et al.  CXCR4 and cancer , 2010, Pathology international.

[89]  W. Sakr,et al.  Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.

[90]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[91]  N. Nock,et al.  Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity , 2009, Cancer Causes & Control.

[92]  N. Nock,et al.  Racial differences in risk of prostate cancer associated with metabolic syndrome. , 2009, Urology.

[93]  J. Witte,et al.  Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California , 2009, Cancer Causes & Control.

[94]  K. McGlynn,et al.  Cancer Incidence in the U.S. Military Population: Comparison with Rates from the SEER Program , 2009, Cancer Epidemiology Biomarkers & Prevention.

[95]  P. Nelson,et al.  Association of Megalin Genetic Polymorphisms with Prostate Cancer Risk and Prognosis , 2008, Clinical Cancer Research.

[96]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[97]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[98]  J. Satagopan,et al.  Differences in clinicopathologic features of prostate cancer between black and white patients treated in the 1990s and 2000s. , 2006, Urology.

[99]  A. Coker,et al.  Stress, coping, social support, and prostate cancer risk among older African American and Caucasian men. , 2006, Ethnicity & disease.

[100]  M. Menon,et al.  Factors contributing to the racial differences in prostate cancer mortality , 2005, BJU international.

[101]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[102]  W. Sakr,et al.  The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy , 2005, Cancer.

[103]  J. Manola,et al.  Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. , 2004, Clinical prostate cancer.

[104]  Timothy F. Donahue,et al.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Desok Kim,et al.  Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. , 2003, The Journal of urology.

[106]  Simon P. Kim,et al.  Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  E. Kinney,et al.  Health Insurance Coverage in the United States , 2002 .

[108]  L. Bernstein,et al.  Changing relationship between socioeconomic status and prostate cancer incidence. , 2001, Journal of the National Cancer Institute.

[109]  L. Baert,et al.  Selective activation of the fatty acid synthesis pathway in human prostate cancer , 2000, International journal of cancer.

[110]  J. Eastham,et al.  Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. , 1999, Urology.

[111]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[112]  J. Stanford,et al.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. , 1997, Cancer research.

[113]  J. Siemiatycki,et al.  Occupational risk factors for prostate cancer: results from a case-control study in Montréal, Québec, Canada. , 1996, American journal of epidemiology.

[114]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.